Individuals with X-linked lymphoproliferative disease are susceptible to severe Epstein-Barr virus (EBV) infections that are often fatal. Mutations in signaling lymphocytic activation molecule-associated protein (SAP) are associated with this illness. We describe a patient with a novel serine-to-proline mutation at aa 57 in SAP and compare the location of the altered amino acid with all known missense mutations in the SAP-encoding SH2D1A gene, including those of 4 additional individuals whose cases have not been described elsewhere. The patient's genetic condition was discovered only after he exhibited an abnormal host response to primary EBV infection that resulted in hemophagocytic lymphohistiocytosis syndrome, which was complicated by marrow aplasia with terminal disseminated aspergillosis.
The familial disorder known as X-linked lymphoproliferative disease (XLP) affects males and often has a rapidly fatal course among individuals who become infected with Epstein-Barr virus (EBV). This condition, which was first recognized 125 years ago by Dr. David T. Purtilo, was originally designated "X-linked recessive, progressive, combined variable immunodeficiency" or "Duncan's disease," after the family in which it was first described [1] . The SH2D1A gene, which encodes signaling lymphocytic activation molecule (SLAM)-as-sociated protein (SAP) and is located on Xq25, was discovered to be mutated in individuals with this condition [2] . The SH2D1A gene consists of 4 exons and encodes a 128-residue protein that consists of a single SH2 domain and a C-terminal 26-aa tail [2] [3] [4] . SAP is expressed in the cytoplasm of T, natural killer, and possibly B cells [5] . The SH2 domain of the SAP motif binds to a consensus motif in the cytoplasmic tail of SLAM family receptors [6] . The SAP SH2 domain is highly conserved and plays a key role in signal transduction by serving as a cytosolic tyrosine kinase.
As a result of mutations in the SH2D1A gene, persons with XLP who become infected with EBV exhibit vigorous polyclonal B and T cell proliferation, in which either EBV-transformed B lymphoblasts become dominant or EBV-reactive T cells proliferate out of control. The bone marrow of such individuals contains numerous phagocytes, a clinical picture that is indistinguishable from that of hemophagocytic lymphohistiocytosis (HLH). Formal criteria have been established for definitive, probable, and possible diagnosis of XLP [7] . Definitive diagnosis of XLP can be made when the patient is male; has died from or has developed lymphoma/Hodgkin disease, immunodeficiency, or aplastic anemia or has developed lymphohistiocytic disorder after acute EBV infection; and has a mutation in the SH2D1A gene. Probable diagnosis can be made when the patient is male; has died from or has developed lymphoma/Hodgkin disease, immunodeficiency, or aplastic anemia or has developed lymphohistiocytic disorder after acute EBV infection; and has maternal cousins, uncles, or nephews with a history of similar diagnoses after acute EBV infection. Possible diagnosis can be made when the patient is male and has died from or has developed lymphoma/Hodgkin disease, immunodeficiency, or aplastic anemia or has developed lymphohistiocytic disorder after acute EBV infection. HLH is characterized by fever of 17 days' duration, splenomegaly, cytopenia affecting at least 2 lineages, hypertriglyceridemia or hypofibrinogenemia, and hemophagocytosis in the bone marrow, liver, or spleen [8] . HLH is an important cause of fever of unknown origin [9] . We present the case of a patient lacking a family history of immunodeficiency who presented with HLH associated with EBV infection and who, we discovered, had a novel mutation in the SH2D1A gene.
CASE REPORT
A previously healthy 18-year-old man was admitted to Vanderbilt Children's Hospital (Nashville, TN) with fever, headache, and night sweats of 1 week's duration. There was no family history of immunodeficiency or early death. The findings of physical examination were normal. The patient's total peripheral blood leukocyte count was 3200 leukocytes/mm 3 (39% neutrophils, 45% lymphocytes, 4% monocytes, and 9% atypical lymphocytes), and the platelet count was 78,000 platelets/mm 3 . Blood samples for bacterial cultures were obtained, and the patient was treated with parenteral ceftriaxone and oral doxycycline. Cultures did not reveal a bacterial organism, and the patient was discharged from the hospital after 3 days with instructions to continue oral doxycycline therapy for treatment of possible rickettsial disease.
The patient returned 1 month later with persistent fever, nausea, vomiting, jaundice, and an ∼7-kg weight loss. Physical examination revealed jaundice and hepatosplenomegaly. The patient's total peripheral blood leukocyte count was 2700 leukocytes/mm 3 (8% neutrophils, 86% lymphocytes, 2% monocytes, and 4% atypical lymphocytes), the hemoglobin concentration was 10.3 g/dL, and the platelet count was 30,000 platelets/mm 3 . His serum glutamic oxaloacetic transaminase level was 969 U/L (normal range, 4-40 U/L), and his serum glutamic pyruvic transaminase level was 880 U/L (normal range, 4-40 U/L). His serum ferritin and triglyceride levels were 8790 ng/mL (normal range, 10-300 ng/mL) and 277 mg/dL (normal range, 35-150 mg/dL), respectively. The results of serologic tests for hepatitis A, B, C, and E viruses were not indicative of previous or current infection. An HIV serum ELISA antibody test was nonreactive, and a quantitative HIV RNA test did not demonstrate HIV RNA. The results of parvovirus B19, Rickettsia, Ehrlichia, and Toxoplasma serum antibody tests were negative. The serum EBV capsid antigen IgM antibody titer was 11:10; the results of ELISA for EBV capsid antigen IgG antibody were positive; and the EBV nuclear antigen antibody titer was !1:10, which suggested recent EBV infection. Abdominal ultrasound revealed hepatosplenomegaly without biliary obstruction. Examination of a bone marrow biopsy specimen revealed edema, with a reduction in normal hematopoietic elements, accompanied by an extensive infiltrate of smallto-medium-sized lymphocytes (figure 1A). Staining for T cell intracellular antigen 1 (figure 1B) and granzyme B (figure 1C) indicated that the bone marrow was infiltrated with CD8 + cytotoxic T lymphocytes (CTLs). In addition, scattered large lymphoid cells and CD20 + B cells were noted ( figure 1D ). Very large lymphoid cells that contained EBV were demonstrated by in situ hybridization for Epstein-Barr virus-encoded small RNA 1 transcripts ( figure 1E ). Examination of a bone marrow specimen from a second biopsy 4 months later revealed a markedly hypocellular marrow with scattered histiocytes containing phagocytosed RBCs (figure 1F).
A diagnosis of EBV-associated HLH was made. The patient was treated with etoposide, cyclosporin A, dexamethasone, and intrathecal methotrexate, in accordance with the HLH-94 protocol [10] , and he experienced transient remission of his symptoms. His hospital course was complicated by EBV-associated necrotizing retinitis that necessitated diagnostic and therapeutic pars plana vitrectomy, with epiretinal membrane peeling, prophylactic endolaser and binocular indirect laser surgery, and implantation of vitreous sustained-release ganciclovir pellets. He developed bacteremia due to Enterococcus (2 occasions) and Klebsiella and disseminated aspergillosis, which ultimately contributed to his death.
METHODS AND RESULTS
Genomic DNA was prepared from PBMCs, and genomic sequences were determined for both the perforin gene, which is altered in some patients with familial HLH [11] , and the SH2D1A gene, which is altered in patients with XLP [2] . No mutations were identified in the perforin gene; however, sequence analysis of the SH2D1A gene revealed a point mutation (T468C) resulting in a serine-to-proline substitution at residue 57 (S57P) in the deduced amino acid sequence of the protein. The patient's family, including the mother, was offered genetic analysis, but declined. The patient has a single female sibling.
To determine whether the SH2D1A mutation in the patient reported here was a known mutation associated with XLP, we reviewed the medical literature for all known SH2D1A gene lesions [2] [3] [4] [12] [13] [14] [15] [16] [17] [18] [19] . In addition, a total of 5 unpublished mutations, including that of the patient described here, were included in the analysis. The previously described mutations associated with XLP and the newly described mutations are shown in table 1. Review of this database revealed that the T486C mutation in the SH2D1A gene is a novel mutation, in comparison with those associated with XLP that have been described elsewhere.
We projected the location of all known missense mutations of SH2D1A associated with XLP onto a ribbon diagram representing the C-a tracing of SAP (figure 2). Serine 57, which is changed to proline in our patient, is located in bD strand of the SH2 domain of SAP (figure 2) [21] . This missense mutation affects a highly conserved amino acid residue within the SH2 domain, changing it to a residue that is never found at this position in related SH2 domains [16] .
DISCUSSION
The familial disorder known as XLP affects males and can be clinically characterized as 1 of 3 types: fatal infectious mononucleosis (FIM; seen in 50% of patients), B cell lymphoma (20%), or dysgammaglobulinemia (30%) [1] . Mutations in the SH2D1A gene, which is located on Xq25, are associated with this condition (table 1) [2-4, 6, 12-20] . The SAP molecule plays a key role in the prevention of overwhelming lymphoproliferation during EBV infection; it acts as a regulator of a [20] . The C-a tracing of SAP is shown as a ribbon diagram in stereo. A sphere is drawn at each amino acid position for which there is a known XLP-associated missense mutation. Each sphere is labeled with its wildtype residue and colored by the no. of known XLP cases associated with a mutation at that position (table 1) . A pure white sphere represents 1 case, and a pure red sphere represents у8 cases. A yellow sphere represents the mutation in the patient described in this article.
small family of receptors on the surface of T, B, and natural killer cells by interacting with SLAM [20] . As a consequence of mutations in SH2D1A, patients with XLP who contract EBV infection exhibit abnormally vigorous polyclonal B and T cell responses. Uncontrolled B cell proliferation leads to death due to secondary organ failure resulting from infiltration with these cells. Uncontrolled proliferation of CTLs leads to widespread tissue necrosis. The bone marrow contains numerous phagocytes, a clinical picture that is indistinguishable from virusassociated HLH syndrome (VAHS). Likewise, patients with XLP and VAHS may have similar initial presentations, and both conditions are often fatal. HLH is characterized by fever of 17 days' duration, splenomegaly, cytopenia affecting at least 2 lineages, hypertriglyceridemia or hypofibrinogenemia, and hemophagocytosis in the bone marrow, liver, or spleen [8] . Supportive diagnostic criteria for HLH include CNS symptoms, adenopathy, jaundice, edema or skin rash, decreased natural killer cell activity, CNS pleocytosis, increased levels of very low-density lipoproteins, decreased levels of high-density lipoproteins, hyperferritinemia, hyponatremia, hypoproteinemia, elevated levels of C-reactive protein, and chronic persistent hepatitis [8] . Not all cases of familial disease fulfill all of the diagnostic criteria, and some patients manifest particular clinical features of HLH only late in the disease course. In the absence of any specific markers of disease, treatment must be initiated on the basis of clinical suspicion [10] .
HLH can be primary (familial or sporadic) or secondary to another illness, such as VAHS, HLH subsequent to bacterial or parasitic infections, malignancy-associated HLH, or macrophage-activation syndrome [21] . HLH may affect multiple members of a family in an autosomal-recessive inheritance pattern. Linkage studies of familial HLH mapped relevant loci to multiple sites, including 10q22, 9q21.3-22, and others [22] . The gene encoding perforin, a molecule contained in granules of CTLs that is required for CTL-mediated destruction of target cells, is located at 10q22. Some cases of familial HLH linked to 10q22 are associated with nonsense or frameshift mutations in the perforin gene [11] . These mutations result in ablation of perforin expression in T cells or decreased expression in asymptomatic carriers. Most of these patients are recognized within the first 4-6 months of life. Our patient presented with symptoms, physical examination findings, and laboratory results consistent with secondary HLH, specifically EBV-associated HLH. He lacked a family history of HLH, FIM, lymphoma, or dysgammaglobulinemia. Despite the lack of a family history of these conditions, sequence analysis of SAP-encoding genomic DNA from our patient revealed a novel point mutation (T468C) resulting in a substitution of a serine with a proline at residue 57 in SAP. This amino acid substitution has not been reported in heathy individuals or any other patient with XLP. Interestingly, most of the point mutations identified in patients with XLP cluster along the SLAMbinding site and at the back of the interacting domain [20] . SLAM makes a parallel b sheet interaction with strand bD of SAP, the strand in which our patient's mutation is found. The side chains of residues in SLAM in this contact area engage in hydrophobic interactions with SAP residues Tyr50, Ile51, and Tyr52 in SAP strand bD [20] . SAP residue Arg55 mediates hydrogen bond formation in phosphate binding in the SAP-SLAM complex [20] . The altered Ser57 residue in our patient, although located in the bD strand, does not directly interact with the SLAM-interacting region. However, an S57P mutation likely destabilizes the folded protein, especially in the region of the bD strand. Unlike the mutations Y54C, T68I, and F87S, our patient's S57P mutation does not directly affect the hydrophobic binding pocket that is the SLAM-interacting domain [16] . Alternatively, the mutation might reduce the half-life of the mRNA or protein [6] .
The approach to therapy for patients with clinical manifestations of HLH includes chemotherapeutic and immunosuppressive agents directed at macrophages and T cells (the HLH-94 protocol) [10] . Induction therapy that includes etoposide, dexamethasone, and intrathecal methotrexate, followed by continuation therapy with etoposide, dexamethasone, and cyclosporin A, are also used. However, curative treatment for most patients with HLH requires allogeneic bone marrow transplantation, especially for those with disease due to a genetic defect. In addition, bone marrow transplantation should be considered for children who have a genetic mutation in SH2D1A that has been associated with XLP, even if they are otherwise healthy.
The case described here illustrates that fulminant EBV infection in patients with XLP is usually fatal, even when aggressive therapy is administered. Although this syndrome is often familial, spontaneous mutations in the SH2D1A gene appear to account for a subset of these patients. Given the gross structural alteration of SAP that is likely to occur with an S57P change, the SH2D1A mutation identified in the patient described here was the likely cause of his abnormal response to EBV infection. Patients with XLP and HLH share many clinical features, and both conditions are often fatal. In light of these observations, we recommend that all patients who have a clinical presentation consistent with HLH be screened for mutations in the SH2D1A and perforin genes, even in the absence of a family history of XLP or HLH. Furthermore, because the initial clinical presentation of the SH2D1A gene defect includes FIM, B cell lymphoma, or hypogammaglobulinemia, genetic testing for a mutation in this gene should be considered for young male patients with any of the 3 presentations.
